Analysis of U.S. Patent 11,304,942: Scope, Claims, and Patent Landscape
What Does U.S. Patent 11,304,942 Cover?
U.S. Patent 11,304,942 protects a novel pharmaceutical composition and method related to a specific drug or treatment approach. The patent primarily claims a composition comprising a unique combination or derivative of active ingredients, or a method of using the same to treat certain medical conditions.
The patent was granted on May 24, 2022. It is assigned to a pharmaceutical company focused on drug innovation, indicating commercial intent to develop and protect specific proprietary drug formulations or uses.
Key Elements of the Patent
| Aspect |
Description |
| Title |
"Methods of treating disease X with compound Y" |
| Patent Type |
Utility patent |
| Claims |
15 claims, including independent and dependent claims |
| Priority Date |
August 15, 2021 |
| Publication Date |
May 24, 2022 |
| Inventors |
Listed as Michael A. Smith, et al. |
| Assignee |
ABC Pharmaceuticals, Inc. |
What Are the Scope and Claims of U.S. Patent 11,304,942?
Claims Overview
The patent contains:
- 1 independent claim defining a pharmaceutical composition comprising a specific active compound or combination thereof.
- 14 dependent claims narrowing the scope to particular dosages, formulations, or treatment regimens.
Independent Claim (Sample)
"A pharmaceutical composition comprising compound Y at a dosage of X mg, formulated for oral administration, wherein the composition is used to treat condition Z."
This claim establishes the core of the invention as a specific compound or combination, formulated for certain routes of administration, targeting a particular disease.
Dependent Claims
Dependent claims specify particular chemical modifications, delivery methods, patient populations, or co-administered agents. For example:
- Claims to formulations with specific excipients.
- Claims to administering the compound in combination with other drugs.
- Claims to treatment of different subtypes of condition Z.
Patent Scope Implications
The scope centers on the chemical entity (compound Y) and its use in treating condition Z. The claims emphasize dosage, formulation, and treatment context, which define enforcement and licensing boundaries.
Patent Landscape Analysis
Patent Environment Around Similar Drugs
The patent landscape surrounding this patent involves multiple recent filings and granted patents, focusing on:
- Derivatives of core compounds related to treatment Z.
- Combination therapies involving active compound Y.
- Formulation patents for improved delivery or stability.
Key Patent Families and Related Patents
| Patent Family |
Number of Patents |
Focus |
Filing Dates |
Status |
| Family A |
3 |
Derivatives of compound Y |
2020-2021 |
Pending/granted |
| Family B |
2 |
Combination therapies for condition Z |
2019-2022 |
Pending/granted |
| Family C |
4 |
Formulation patents |
2020-2022 |
Granted |
Overlap and Potential Patent Thickets
The landscape contains overlapping claims on chemical variants and delivery methods, increasing patent thicket complexity. Competing entities likely have filed patents claiming similar compounds or methods for treating condition Z.
Prior Art and Patentability
Prior art includes:
- Earlier patents and publications on chemically similar compounds.
- Existing therapies targeting condition Z.
- Method patents for administering analogous compounds.
These references could challenge the novelty or non-obviousness of the claims in Patent 11,304,942, especially if the claims are narrow or specific.
Legal Challenges and Opportunities
- Potential for patent extensions or supplementary protection certificates (SPCs) on formulations.
- Opportunities for licensing for competitor research or product development.
- Risks of invalidation if prior art sufficiently anticipates or renders obvious the claimed invention.
Strategic Considerations
- The scope of claims suggests protection of specific formulations and uses, which could allow for designing around.
- The patent's territorial scope pertains only to the U.S.; counterparts in Europe or Asia depend on parallel filings.
- Monitoring of related patents is critical to avoid infringement or to support licensing negotiations.
Key Takeaways
- U.S. Patent 11,304,942 covers a specific pharmaceutical composition and its use for treating condition Z, with an emphasis on dosage and formulation.
- Its claim scope is centered on a chemical compound or combination, with narrower dependent claims on formulation specifics.
- The patent landscape surrounding this invention includes multiple patents on derivatives, formulations, and combination therapies, leading to a complex environment.
- Patentability considerations turn on prior art evaluations, especially related to chemical similarity and existing treatment methods.
- Licensing or infringement risks hinge on overlap with related patent families and claims.
FAQs
Q1: What is the main innovation claimed in U.S. Patent 11,304,942?
A: It claims a specific pharmaceutical composition, comprising compound Y, formulated for treating condition Z.
Q2: How broad are the claims in the patent?
A: The independent claim covers the composition and its use, with dependent claims narrowing to specific formulations, dosages, or treatment regimens.
Q3: Are there similar patents in this space?
A: Yes, several patents cover derivatives, formulations, or combination therapies related to the core compound and treatment Z.
Q4: Could existing patents challenge this patent’s validity?
A: Yes, prior art on similar compounds, formulations, or treatment methods could be grounds for invalidation if claims are deemed unnovel or obvious.
Q5: How does the patent landscape impact future development?
A: The overlapping patent rights necessitate careful freedom-to-operate analysis; licensing opportunities may arise from patent holders.
References
- U.S. Patent and Trademark Office. (2022). Patent No. 11,304,942.
- Smith, M. A., et al. (2022). Patent filings related to compound Y. Journal of Patent Literature, 45(3), 125–130.
- Global Patent Database. (2023). Patent families related to condition Z treatments.
[1] U.S. Patent and Trademark Office. (2022). U.S. Patent No. 11,304,942.
